key: cord-0994744-53ceg6fg
authors: Stanley, S.; Hamel, D. J.; Wolf, I. D.; Riedel, S.; Dutta, S.; Cheng, A.; Kirby, J. E.; Kanki, P. J.
title: Limit of Detection for Rapid Antigen Testing of the SARS-CoV-2 Omicron Variant
date: 2022-01-30
journal: nan
DOI: 10.1101/2022.01.28.22269968
sha: 20713565ffae580c8170e9fdc9f31d7f6bfc223a
doc_id: 994744
cord_uid: 53ceg6fg

There has been debate in the literature about the ability of antigen tests to detect the SARS-CoV-2 Omicron variant including indication on the US Food and Drug administration website that antigen tests may have lower sensitivity for the Omicron variant without provision of data or the potential scale of the issue (see https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests - omicronvariantimpact, accessed 1/27/2022). Here we determined the limit of detection (LoD) for the Omicron variant compared with the WA1 strain used for LoD studies described in the Instructions for Use for all Emergency Use Authorization (EUA)-approved antigen tests. Using live virus (to avoid artifactual findings potentially obtained with gamma-irradiated or heat-killed virus) quantified by plaque forming units (PFU), we examined the analytical sensitivity of three antigen tests widely used in the United States: the Abbott Binax Now, the AccessBio CareStart , and LumiraDx antigen tests. We found that the 95% detection threshold (LoD) for antigen tests was at least as good for Omicron as for the WA1 strain. Furthermore, the relationship of genome copies to plaque forming units for Omicron and WA1 overlap. Therefore, the LoD equivalency also applies if the quantitative comparator is genome copies determined from live virus preparations. Taken together, our data support the continued ability of the antigen tests examined to detect the Omicron variant.

comparator is genome copies determined from live virus preparations. Taken together, our data 48 support the continued ability of the antigen tests examined to detect the Omicron variant. 49 50 51 52 53 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 To bolster COVID-19 pandemic mitigation efforts, the U.S. Food and Drug Administration 54 (FDA) issued Emergency Use Authorization (EUA) for easy-to-use rapid antigen tests 55 instrumental for diagnosis and surveillance of SARS-CoV-2 infection (1-2). Unlike sensitive 56 molecular tests that detect multiple SARS-CoV-2 genes, antigen tests target a singular yet 57 genetically-conserved nucleocapsid viral protein (3-6). As the pandemic continues, some 58 hypothesized that new SARS-CoV-2 variants might compromise antigen test performance. This 59 concern heightened with the spread of Omicron, the B.1.1.529 variant of concern (VoC) that 60 caused 99.5% of SARS-CoV-2 infections in the United States early 2022 (7-8). Beyond the 61 striking 36 amino acid mutations in the spike protein, Omicron also harbors P13L, Δ31-33, 62 R203K, and G204R nucleocapsid mutations (9). The limit of detection (LoD) of many FDA EUA 63 antigen tests were established with gamma-irradiated or heat-inactivated preparations of the USA 64 WA1/2020 (WA1) reference strain (13) lacking nucleocapsid mutations. This includes at-home 65 lateral flow tests like the BinaxNOW COVID-19 Ag Card (Abbott Diagnostics Scarborough, Inc., 66

Scarborough, ME) and the CareStart COVID-19 Antigen Home Test (Access Bio, Inc., Somerset, 67 NJ), and the LumiraDx SARS-CoV-2 Ag Test (LumiraDx UK Ltd., Alloa, Great Britain), a 68 microfluidic immunofluorescence assay for clinical laboratory testing (10-12). In the present 69 study, we used cultured plaque-titered live Omicron and WA1 virus to assess differences in the 70

LoD with the Binax, CareStart, and LumiraDx tests. 71

The WA1 (13) and Omicron lh01 (NCBI accession OL719310) virus were titered with 72 standard plaque (13) and calibrated RT-qPCR (14) assays. Ten-fold serial dilutions in PBS ranging 73 from 2.5x10 4 to 2.5 plaque forming units (PFU)/mL were applied to swabs in 50uL volumes and 74 tested in triplicate according to manufacturer instructions (10-12). Binax and CareStart kits 75 contained all required consumables; iClean foam swabs (Supera CY-FS742, Houston, TX) were 76 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2022. ; https://doi.org/10.1101/2022.01.28.22269968 doi: medRxiv preprint used with the LumiraDx test. After identifying the lowest 10-fold dilution with three replicate 77

positive tests, we iteratively tested 3-fold dilutions around this concentration until identifying the 78 lowest dilution (the LoD) in which at least 19 of 20 replicates (≥95%) were positive. 79

The LumiraDx LoD for both Omicron and WA1 was 2.5x10 2 PFU/mL (12.5 PFU/swab or 80 1.0 x10 6 genome copies (gc)/swab) (Fig. 1) . The Binax LoD was 8.3x10 1 PFU/mL (4.2 PFU/swab, 81 3.4x10 5 gc/swab) and 2.5x10 2 PFU/mL (12.5 PFU/swab, 1.0 x10 6 gc/swab) for Omicron and WA1, 82 respectively. The CareStart LoD was 2.8x10 3 PFU/mL (1.4x10 2 PFU/swab, 1.1x10 7 gc/swab) and 83 8.3x10 3 PFU/mL (4.2 x10 2 PFU/swab, 3.5x10 7 gc/swab) for Omicron and WA1, respectively. The 84 nearly identical relationship of PFU to genome copies for each variant indicates that the Omicron 85 variant mutations do not change undelrying diagnostic relationships and paramaters ( Figure 2) . 86

Our use of live virus, analyte volume, and swab type may explain the slight discrepancy with the 87 manufacturers' LoDs. Our findings are consistent with similar investigations, but these studies fell 88

short of the FDA's EUA requirement of 20 LoD replicates or included tests unavailable in the 89 United States (15) (16) (17) . In all, we demonstrate that the rapid antigen tests evaluated detect Omicron 90 effectively, allaying concerns on the impact of the nucleocapsid mutations. Rapid antigen tests 91 remain critical public health tools towards reducing SARS-CoV-2 variant transmission. 92 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2022. ; https://doi.org/10.1101/2022.01.28.22269968 doi: medRxiv preprint Instructions for Use (IFU) documents (10-12), converted from TCID50/mL to PFU/mL by 95 multiplying the TCID50/mL by 0.7, a standard conversion based on the Poisson distribution: 96

LumiraDx (32 TCID50/mL, 2.2x10 1 PFU/mL); Binax (140 TCID50/mL, 9.8x10 1 PFU/mL), 97

CareStart (800 TCID50/mL, 5.6x10 2 PFU/mL). 98 99 100 

Omicron . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2022. ; https://doi.org/10.1101/2022.01.28.22269968 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 30, 2022. ; https://doi.org/10. 1101 /2022 

Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States

SARS-CoV-2 Antigen Tests Predict Infectivity Based 155 on Viral Culture: Comparison of Antigen, PCR Viral Load, and Viral Culture

Detection of the omicron variant virus with the 159

Sensitivity of SARS-CoV-2 antigen-detecting rapid tests for Omicron variant

Assessment of the analytical sensitivity of ten lateral flow devices against the 167

SARS-CoV-2 omicron variant

1. The U.S. Food and Drug Administration. In Vitro Diagnostics EUAs -Antigen Diagnostic 108Tests for SARS-CoV-2. Available at: https://www.fda.gov/medical-devices/coronavirus-109 disease- 2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-110 diagnostics-euas-antigen-diagnostic-tests-sars-cov-2. Accessed 24 January 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 30, 2022. ; https://doi.org/10.1101/2022.01.28.22269968 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted January 30, 2022. ; https://doi.org/10. 1101 /2022